Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

– Transactions Provide Karyopharm with $100 Million of Financial Flexibility and Additional Capital –

– Preliminary Total Revenue and U.S. XPOVIO^® (selinexor) Net Product Revenue for the Third Quarter of 2025 Expected to be in the Range of $42 to $44 Million and Approximately $32 Million, Respectively –

Read more at prnewswire.com